Avermectin

As a cornerstone drug for antiparasitic infection in the agriculture and animal husbandry sector, abamectin belongs to the macrolide disaccharide derivatives. It enhances the release of γ-aminobutyric acid from the nerve endings of invertebrates, blocks nerve signal transmission, and paralyzes and kills parasites. It has high selectivity for arthropod and nematode parasites and extremely low toxicity to mammals. It is widely clinically used for the prevention and control of internal and external parasites in livestock and poultry. Meanwhile, it is also a core biogenic pesticide for killing pests such as red spiders and root-knot nematodes in agricultural production. Some dosage forms can also be used for the treatment of human scabies and onchocerciasis, covering three major application scenarios of animal husbandry, agriculture and public health.

At present, the annual global market size of abamectin exceeds RMB 6 billion, and the compound annual growth rate in the past five years has maintained at around 4.8%. The industry presents a highly concentrated pattern. Chinese enterprises account for more than 90% of the global production capacity supply, and the total market share of the top 3 enterprises exceeds 75%. Driven by the increasing scale rate of downstream livestock breeding, the continuously released demand for biopesticides in green agriculture, and the increased investment in驱虫保健 at the breeding end after African swine fever, the annual growth rate of domestic demand for abamectin API remains above 6%, and the price shows a cyclical fluctuation characteristic with the supply and demand relationship of the upstream and downstream.

The original developer of abamectin is Merck Sharp & Dohme (MSD) of the United States, with the original brand name "Ivomec". The core compound patent expired globally in 1999. Currently, the main marketed dosage forms include injections, premixes, pour-ons, tablets, etc., and common specifications cover different contents such as 0.5%, 1%, 2%, etc. Its original preparation has been included in the FDA Reference Listed Drug Catalog, and there are more than 200 domestic preparation approvals. As of now, there are 39 valid registration numbers of abamectin on the API registration platform of China NMPA, most of which have obtained the A status identifier, which can meet the associated review requirements of domestic preparation enterprises. (Data as of September 2024, please refer to the official website of CDE for the latest information)

In response to the quality control needs of the entire abamectin industry chain, CATO provides a full set of impurity reference standards for this API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can be directly used for API purity testing, qualitative and quantitative analysis of impurities, and preparation stability studies, helping enterprises quickly pass relevant registration reviews.